{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:15:32Z","timestamp":1784862932673,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Autologous stem cell transplantation (ASCT) has improved progression\u2010free survival (PFS) and overall survival in eligible patients with newly diagnosed multiple myeloma (NDMM); however, relapse occurs. Maintenance therapy with lenalidomide (Len\u2010Mt) extends survival and delays relapse and the subsequent initiation of costly second\u2010line regimens. Here, we report the cost\u2010effectiveness of Len\u2010Mt following ASCT from a Dutch healthcare service perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A partitioned survival model was developed to assess the lifetime costs and benefits for patients with NDMM. Efficacy was taken from a pooled meta\u2010analysis of clinical trial data. Costs and subsequent therapy data were taken from sources appropriate for the Dutch market.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Lenalidomide produced a quality\u2010adjusted life year gain of 2.46 and a life year gain of 2.79 vs no maintenance treatment. The cost of lenalidomide was partially offset by savings of EUR 77\u00a0462 in subsequent treatment costs. The incremental cost\u2010effectiveness ratio of Len\u2010Mt vs no maintenance treatment was EUR 30\u00a0143. Key model drivers included subsequent therapies, dosing schedule, and time horizon.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lenalidomide is cost\u2010effective after ASCT vs no maintenance therapy in the Netherlands. By extending PFS, lenalidomide delays the cost burdens associated with relapse and subsequent treatment lines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13497","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T04:14:15Z","timestamp":1595564055000},"page":"635-645","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco\u2010economic assessment"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-5203","authenticated-orcid":false,"given":"Carin A.","family":"Uyl\u2010de Groot","sequence":"first","affiliation":[{"name":"Erasmus School of Health Policy &amp; Management Erasmus University Rotterdam Rotterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Ramsden","sequence":"additional","affiliation":[{"name":"BresMed Health Solutions Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lee","sequence":"additional","affiliation":[{"name":"BresMed Health Solutions Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Boersma","sequence":"additional","affiliation":[{"name":"Formerly Celgene B.V., A Bristol\u2010Myers Squibb Company Utrecht Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology Cancer Center Amsterdam Amsterdam UMC, Vrije Universiteit Amsterdam Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Dhanasiri","sequence":"additional","affiliation":[{"name":"Celgene International, A Bristol\u2010Myers Squibb Company Boudry Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2961"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.23"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590166"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"e_1_2_10_11_1","unstructured":"Integraal Kankercentrum Nederland.The Netherlands Cancer Registry. Dutch cancer figures. (Updated: 2 February 2018).https:\/\/www.cijfersoverkanker.nl. Accessed September 2018."},{"key":"e_1_2_10_12_1","first-page":"3405","article-title":"Lenalidomide maintenance therapy post\u2010autologous stem cell transplant: a healthcare cost\u2010impact analysis in Europe","volume":"130","author":"Jackson G","year":"2017","journal-title":"Blood"},{"key":"e_1_2_10_13_1","article-title":"Ixazomib\u2010thalidomide\u2010low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON\u2010126\/NMSG21.13 trial","author":"Zweegman S","year":"2020","journal-title":"Haematologica"},{"key":"e_1_2_10_14_1","unstructured":"Nederland Zorginstituut.Cost\u2010effectiveness in practice.2015.https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2015\/06\/16\/cost\u2010effectiveness\u2010in\u2010practice. Accessed October 2019."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2018.04.001"},{"key":"e_1_2_10_16_1","unstructured":"Nederland Zorginstituut.Guideline for economic evaluations in healthcare.2016.https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline\u2010for\u2010economic\u2010evaluations\u2010in\u2010healthcare. Accessed October 2019."},{"key":"e_1_2_10_17_1","unstructured":"LatimerN.NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials \u2010 extrapolation with patient\u2010level data.2013.http:\/\/www.nicedsu.org.uk\/NICE%20DSU%20TSD%20Survival%20analysis.updated%20March%202013.v2.pdf. Accessed August 2016."},{"key":"e_1_2_10_18_1","unstructured":"Stichting Hemato\u2010Oncologie voor Volwassenen Nederland (HOVON).Richtlijn Behandeling Multipel Myeloom 2019.2019. (Updated 21 March 2019).https:\/\/www.hematologienederland.nl\/hematline\/node\/816. Accessed October 2019."},{"key":"e_1_2_10_19_1","unstructured":"Nederland Zorginstituut.Daratumumab (Darzalex\u00ae) voor de behandeling van volwassen pati\u00ebnten met multipel myeloom die minstens \u00e9\u00e9n eerdere behandeling hebben gehad: in combinatie met bortezomib en dexamethason; in combinatie met lenalidomide en dexamethason. (Onze referentie ACP 70\u20134).https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/adviezen\/2017\/11\/gvs\u2010advies\u2010oordruppels\u2010bij\u2010gehoorgangontsteking\u2010otitis\u2010externa\/pakketadvies\u2010daratumumab\u2010darzalex\u2010bij\u2010multipel\u2010myeloom\/combinatiebehandelingen+van+daratumumab+%28Darzalex%29+voor+de+behandeling+van+volwassen+pati%C3%ABnten+met.pdf. Accessed October 2017."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3446-y"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2406"},{"issue":"1","key":"e_1_2_10_22_1","first-page":"598","article-title":"Assessing real\u2010world treatment patterns, outcomes and resource use across Europe in newly diagnosed multiple myeloma (NDMM) patients post autologous stem cell transplant","volume":"102","author":"Ashcroft J","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12020"},{"key":"e_1_2_10_24_1","unstructured":"Nederland Zorginstituut.Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg.2016.https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2016\/02\/29\/richtlijn\u2010voor\u2010het\u2010uitvoeren\u2010van\u2010economische\u2010evaluaties\u2010in\u2010de\u2010gezondheidszorg\/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidszorg+%28verdiepingsmodules%29.pdf. Accessed July 2017."},{"key":"e_1_2_10_25_1","unstructured":"Nederland Zorginstituut.Medicijnkosten.2017.https:\/\/www.medicijnkosten.nl\/. Accessed January 2017."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586130-000000000-00000"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360"},{"key":"e_1_2_10_28_1","unstructured":"Statistics Netherlands.Deaths; underlying cause of death (shortlist) sex age.2015.http:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLEN&PA=7052eng&D1=0 92&D2=1\u20102&D3=1\u201021&D4=l&LA=EN&HDR=G1 G2 G3&STB=T&VW=T. Accessed November 2016."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000045"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:36:32Z","timestamp":1693564592000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/ejh.13497"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13497","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"2020-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}